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Tuberculosis Treatment in Patients with 
Comorbidities
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Tuberculosis is a significant infectious problem in elderly patients with comorbidities in Korea. The age-associated 
diseases such as malignancy and diabetes mellitus may increase the risk of tuberculosis in this population. The 
medication treatments of tuberculosis in patients with comorbidities can cause adverse reactions to antituberculosis 
drugs and inadequate treatment responses. Thus, clinicians must carefully monitor the toxicity of antituberculosis 
therapy and the efficacy of treatment in patients with comorbidities. 
Keywords: Tuberculosis; Therapeutics; Comorbidity
ated with the treatment of tuberculosis. Chronic liver dis-
ease is known to increase the risk of DILI. DILI in patients 
with advanced liver disease is potentially serious, even life-
threatening3. Thus, clinicians must carefully monitor hepatic 
function in patients with liver disease during the treatment of 
tuberculosis. The choice of the treatment regimen used in the 
setting of liver disease depends on the severity of both the liver 
disease and the tuberculosis (Table 1)2-4.
Lee et al.5 reported that tuberculosis treatment in hepatitis 
B surface antigen (HBsAg)-positive inactive carriers can be 
performed in the usual manner, using standard short-course 
regimens of isoniazid, rifampin, ethambutol, and/or pyrazin-
amide with careful monthly monitoring of liver function. In 
that study, the authors showed that DILI occurred more fre-
quently in HBsAg carriers (9 of 110 carriers, 8%) than in con-
trol subjects (4 of 97 controls, 4%). However, after the recovery 
of liver function, isoniazid and rifampin were successfully 
reintroduced as therapy. Park et al.6 reported on the treatment 
of tuberculosis in patients with chronic hepatitis and cirrhosis. 
In that study, the authors showed that hepatotoxic antituber-
culosis drugs might be safely used in patients with chronic 
liver disease, including compensated cirrhosis, if the number 
of hepatotoxic drugs used was appropriately adjusted.
Renal Insufficiency and  
End-Stage Renal Disease
Renal insufficiency complicates the treatment of tubercu-
losis because some antituberculosis drugs are cleared by the 
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Introduction
Tuberculosis is a significant infectious problem in elderly 
patients with comorbidities in Korea1. The incidence of tuber-
culosis is increasing in older patients, and some have multiple 
comorbidities. This review summarizes the treatment of tu-
berculosis in patients with comorbidities including hepatic 
disease, chronic kidney disease, solid-organ transplantation, 
and solid malignant disease. This review is based on the Ko-
rean Guidelines for Tuberculosis, first edition, 20112.
Hepatic Disease
Drug-induced liver injury (DILI) is a problem associ-
REVIEW http://dx.doi.org/10.4046/trd.2014.76.6.257ISSN: 1738-3536(Print)/2005-6184(Online) • Tuberc Respir Dis 2014;76:257-260
257
Address for correspondence: Young Ae Kang, M.D.
Division of Pulmonology, Department of Internal Medicine, Yonsei 
University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-
752, Korea
Phone: 82-2-2228-1986, Fax: 82-2-393-6884
E-mail: mdkang@yuhs.ac
Received: Mar. 24, 2014
Revised: Mar. 31, 2014
Accepted: Apr. 7, 2014
cc  It is identical to the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0/).
YA Kang
258 Tuberc Respir Dis 2014;76:257-260 www.e-trd.org
kidney. Management may be further complicated by the re-
moval of some antituberculosis drugs via hemodialysis3. Thus, 
clinicians should carefully monitor the potential development 
of drug-induced toxicity and the efficacy of antituberculosis 
treatment in patients with renal insufficiency. Some antituber-
culosis drugs require adjustment of their dosing and adminis-
tration time intervals. Vitamin B6 should be given to these pa-
tients to prevent peripheral neuropathy due to isoniazid. The 
recommendations for adjustment of antituberculosis drug are 
shown in Table 22,3 and Table 37.
Table 1. Possible regimen of antituberculosis treatment in patients with hepatic disease*
Underlying hepatic disease Possible regimen
Inactive HBsAg carrier 
Inactive HCV carrier
Past history of acute hepatitis
Alcohol drinker
Standard short-course regimen
    1) 6HREZ/4HR(E)
    2) 9HRE
Monitor liver function 
Stop drinking
Chronic liver disease with stable liver function 9HRE Monitor liver function
Advanced liver disease 
    Unstable liver function
    Hepatic encephalopathy
1) Two hepatotoxic drugs
     9HRE
     6-9 REZ
     2HRES/6HR
2) One hepatotoxic drug
     12-18 RE/FQ/CS/injectables
     2HES/10HE
3) No hepatotoxic drugs
     18-24 E/FQ/CS/injectables
Refer to experts
*Based on the Korean guidelines for tuberculosis, 1st edition (2011)2, Treatment of tuberculosis guidelines, 4th edition (2010)4, and American 
Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis (2003)3.
HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; H: isoniazid; R: rifampin; E: ethambutol; Z: pyrazinamide; S: streptomycin; FQ: 
fluoroquinolone; CS: cycloserine.
Table 2. Dosing recommendations for adult patients with reduced renal function and for adult patients undergoing 
hemodialysis*
Drug Change in frequency
Recommended dose and frequency for patients with Ccr of 
<30 mL/min or patients undergoing hemodialysis
Isoniazid No change 300 mg once daily
Rifampin No change 600 mg once daily
Pyrazinamide Yes 25–35 mg/kg three times per week
Ethambutol Yes 15–25 mg/kg three times per week 
Levofloxacin Yes 750–1,000 mg three times per week
Moxifloxacin No change 400 mg once daily
Cycloserine Yes 250 mg once daily or 500 mg three times per week
Ethionamide No change 250–500 mg once daily
p-Aminosalicylic acid No change 4 g twice daily
Streptomycin Yes 12–15 mg/kg two or three times per week
Capreomycin Yes 12–15 mg/kg two or three times per week
Kanamycin Yes 12–15 mg/kg two or three times per week
Amikacin Yes 12–15 mg/kg two or three times per week
*Reprinted from Blumberg et al.3 Am J Respir Crit Care Med 2003;167:603-62, with permission of the American Thoracic Society. Copyright © 
2014 American Thoracic Society; reprinted from Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers 
for Disease Control and Prevention2.
Ccr: creatinine clearance.
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Solid-Organ Transplant
The risk for tuberculosis in patients with solid-organ trans-
plantation is estimated to be 20 to 74 times greater than that 
in the general population8. Because of the challenge of treating 
active tuberculosis after transplantation, every effort must be 
made to diagnose and treat active tuberculosis before trans-
plantation. The standard short-course treatment for active tu-
berculosis is recommended in patients undergoing transplan-
tation8. The major difficulty in administering antituberculosis 
drugs to transplant patients is drug-drug interactions involv-
ing rifampin. Rifampin is a strong inducer of the microsomal 
enzymes that metabolize cyclosporine, tacrolimus, sirolimus, 
and corticosteroids. It may be difficult to maintain adequate 
levels of immunosuppressive drugs while using rifampin. Suc-
cessful use of rifampin has been reported in transplant recipi-
ents, but the doses of cyclosporine, tacrolimus, and sirolimus 
must be increased at least two- to five-fold8.
Solid-Organ Malignancy
There are no specific guidelines for the treatment of tuber-
culosis in patients with solid-organ malignancy. Standard 
treatment for tuberculosis is recommended in this popula-
tion. Kim et al.9 reported that the radiographic and clinical 
treatment responses during anticancer chemotherapy were 
not clinically different between tuberculosis-infected patients 
with (n=24) and without (n=48) solid-organ malignancy.
Conclusion
Tuberculosis is still a significant public health concern in 
Korea. The growing elderly population with higher incidences 
of comorbidities has a risk of developing tuberculosis. Clini-
cians must monitor the side effects of and response to antitu-
berculosis therapy in patients with comorbidities.
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